March 26, 2026 – Thermo Fisher Scientific Inc. has introduced a strategic partnership with SHL Medical, a number one supplier of superior drug supply techniques, along with an enlargement of sterile filling and closing meeting capabilities for autoinjectors at its Ridgefield, New Jersey location. Collectively, these investments create a completely built-in, US-based providing that features sterile manufacturing, machine meeting and business packaging for drug mixture merchandise.

Demand for patient-centric, self-administered injectable therapies continues to develop throughout a number of therapeutic areas, together with autoimmune ailments, inflammatory circumstances and different persistent ailments. To satisfy this want, Thermo Fisher is increasing pre-filled syringe (PFS) filling and machine meeting in Ridgefield. On the similar time, the strategic partnership with SHL Medical permits the mixing of SHL Medical’s Molly® auto-injector platform with Thermo Fisher’s sterile manufacturing community, making a seamless, end-to-end answer from drug product to completed product.

Thermo Fisher acquired the Ridgefield plant from Sanofi in September 2025 as a part of its technique to strengthen its US manufacturing footprint. The location is being developed as a number one North American hub for built-in sterile fill ending, closing meeting and packaging of autoinjectors, growing home capability to assist buyer provide chains.

Beneath the strategic, non-exclusive partnership, Thermo Fisher and SHL Medical will present built-in assist for SHL Medical’s Molly® auto-injector platform on the Ridgefield website, together with closing meeting, packaging and distribution of the machine.

Proceed studying